Advertisements

Onsior for Dogs

Quick links to important sections

Onsior for Dogs

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Onsior for Dogs

Quick Facts

Property Description
Active ingredient Robenacoxib (INN)
Form Tablets, Injectable Solution
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Target Function Analgesia, Anti-inflammation
Origin Synthetic

What Type of Medicine is Onsior for Dogs?

Onsior for Dogs is a prescription-only synthetic veterinary medicine designated for use in canine patients. It is categorized within the major pharmacological class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), specifically known as a member of the coxib class. This medicine is classified as a highly selective Cyclooxygenase-2 (COX-2) inhibitor, a key feature that is crucial to its function. This selectivity means the drug targets the enzymes that cause inflammation while largely sparing those that protect the stomach and kidneys.

Composition and Available Pharmaceutical Forms

The core of the medicine is the single active ingredient, Robenacoxib (INN), a synthetic compound that defines its therapeutic action. Robenacoxib is formulated as a veterinary medicine in two principal dosage forms for administration to dogs. These forms include a tablet preparation intended for oral administration and an injectable solution designed for parenteral administration by a veterinarian. The oral tablets are typically flavored, a feature designed to enhance acceptance in the canine patient group, which is a key differentiating factor for ease of long-term use compared to unpalatable formulations.

Core Function and Mechanism Principle

The general purpose of Robenacoxib is the effective modulation of the inflammatory response in dogs, providing both an analgesic and anti-inflammatory effect, particularly for discomfort associated with musculoskeletal disorders. Robenacoxib is used to control pain and inflammation following soft tissue surgery in dogs. The medicine works by the high-level mechanism principle of selective inhibition of COX-2, limiting the production of prostaglandins that mediate swelling and pain signals. This focused approach targets the source of inflammation.

Regulatory References

  1. Efficacy and safety of oral robenacoxib in dogs (PMID: 28651573)
Advertisements

What side effects are possible with Onsior for Dogs?

Possible Side Effects and Safety Information

The safety profile for Robenacoxib (Onsior for Dogs) is strictly defined by government regulatory documents, outlining the potential adverse reactions, their documented frequencies, and mandated restrictions for use. Adverse reactions are classified according to frequency, with most effects categorized as Common and typically involving the digestive system.

Common adverse reactions listed in regulatory information include soft faeces, vomiting, diarrhea, decreased activity (lethargy), and decreased appetite (anorexia). These gastrointestinal disturbances are often described as transient and may be observed primarily at the beginning of treatment, potentially resolving without intervention.

Adverse effects are officially grouped into System-Organ Classes, primarily affecting Gastrointestinal Disorders, Renal and Urinary Disorders, and Hepatobiliary Disorders, with transient elevations in liver and kidney parameters sometimes noted.

Regulatory documentation also defines Rare but potentially serious adverse reactions, which include gastrointestinal ulceration and associated haemorrhage (bleeding).

Safety-Related Restrictions and Contraindications The official profile mandates strict limitations on the use of Robenacoxib. It is formally restricted in dogs with pre-existing hepatic, renal, or cardiac impairment, and in dogs that are dehydrated, hypovolemic, or hypotensive due to the risk of increased kidney toxicity. Use is also prohibited in pregnant or lactating bitches, in dogs under three months of age or below 2.5 kg body weight, and when concurrently administering other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or corticosteroids.

Advertisements

Overdose and Emergency Response

Onsior for Dogs Overdose and when to seek help

The official regulatory profile for Robenacoxib overdose is defined by the documented risks associated with the cyclo-oxygenase inhibitory Non-Steroidal Anti-Inflammatory Drug (NSAID) class.


Overdose Manifestations and Risks

Potential signs of over-exposure involve documented risks to multiple physiological systems. The primary manifestations include potential gastrointestinal toxicity, kidney toxicity, and liver toxicity. These toxicities may escalate to severe and life-threatening outcomes such as gastrointestinal ulcerations or perforations and hepatic necrosis. Observations in high-dose studies have also noted localized manifestations like oedema and erythema. Dogs with existing renal, cardiovascular, and/or hepatic dysfunction, or those otherwise considered sensitive or compromised, are identified in official labeling as the patient population at greatest risk for adverse effects from an overdose exposure.


Required Emergency Actions

Regulatory authorities mandate that immediate medical attention be sought if an overdose of Onsior for Dogs is witnessed or suspected. It is required to contact a veterinarian or animal poison control center immediately for professional management. The official context states that treatment should consist of symptomatic and supportive measures, as no specific antidote is known for Robenacoxib overdose. This emphasizes the necessity of prompt veterinary intervention to address potential organ damage.

Advertisements

Therapeutic Uses of Onsior for Dogs

What Onsior for Dogs Treats: Main Uses and Benefits

Robenacoxib is commonly used across conditions characterized by episodic or fluctuating symptoms related to pain and inflammation. Its uses include the treatment of discomfort associated with chronic osteoarthritis in dogs, as well as the management of pain and inflammation during the recovery phase following soft tissue or orthopaedic surgery.

The primary therapeutic benefit is to ease symptomatic manifestations such as lameness, joint stiffness, and postoperative swelling. Applied in contexts where additional management of discomfort is required, the medication is intended to provide supportive relief when symptoms interfere with routine activities.

“Offering symptomatic relief helps dogs cope more steadily with difficult episodes.”

This assistance contributes to improved comfort during periods of heightened symptoms, and supports functional stability, especially for older dogs with chronic conditions.


Quick Fact: Relief for Musculoskeletal Pain

Therapeutic Focus Common Scenarios Symptom Relief
Chronic Osteoarthritis, degenerative joint issues Stiffness, persistent joint discomfort
Acute Post-surgical recovery (soft tissue/orthopaedic) Acute pain, localized swelling

Regulatory References

  1. European Medicines Agency (EMA) registration details
Advertisements

Eligibility and Restrictions for Use

Onsior (robenacoxib) is an oral or injectable medicine for dogs with specific regulatory restrictions on its use, strictly based on official government labeling (e.g., FDA, EMA).

Contraindications (Must Not Use)

Onsior is contraindicated and must not be used in dogs with a known hypersensitivity to robenacoxib or other NSAIDs. Use is also prohibited in dogs suffering from gastrointestinal ulceration or significant hepatic disease (liver disease).

Age, Weight, and Reproductive Status

The safe use of Onsior has not been established in certain populations. This includes dogs younger than 3 or 4 months of age (depending on the formulation and region) and dogs weighing less than 2.5 kg (approx 5.5 lbs). Additionally, the medicine must not be used in pregnant or lactating bitches, and its safety has not been established in dogs used for breeding.

Restricted Use and Monitoring

Additional risks are involved when using Onsior in dogs with impaired cardiac or renal function, or in dogs that are dehydrated, hypovolaemic, or hypotensive. If use cannot be avoided in these dogs, they require careful veterinary monitoring as stated in official product information.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Robenacoxib (Onsior for Dogs) establishes specific restrictions regarding co-administration with other medicines, primarily due to the risk of additive adverse effects. Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or Glucocorticosteroids (Corticosteroids) is strictly prohibited and classified as a formally contraindicated combination in regulatory labeling.

Timing and Pharmacodynamic Interactions

A treatment-free washout period of at least 24 hours must be observed when transitioning a dog from any other anti-inflammatory medicine to Robenacoxib; this period must consider the pharmacokinetics of the previous drug. Concurrent use with potentially nephrotoxic medicines or agents acting on renal blood flow, such as Diuretics or ACE Inhibitors, should be monitored or avoided due to a documented increased risk of renal toxicity.

Exposure and Food Interaction Notes

The regulatory label notes that co-administration of highly protein-bound active substances may result in competition for protein binding sites. Furthermore, the systemic bioavailability (AUC and Cmax) of the oral tablet is officially documented to be reduced when administered with food. Specific caution is required when administering kidney-affecting drugs to dogs that are dehydrated, hypovolaemic, hypotensive, or have impaired cardiac or renal function, as this specific population carries additional interaction risks.

Advertisements

Mechanism of Action

Targeting the COX-2 Inflammatory Enzyme

The primary mechanism involves the highly selective and competitive inhibition of the Cyclooxygenase-2 (COX-2) enzyme, the molecular target responsible for the inducible, massive production of key inflammatory mediators. By blocking COX-2, the drug directly interferes with the early molecular steps of the Arachidonic Acid Cascade, thereby interfering with the signaling sequence initiated by COX-2 activity.

Modulating Prostaglandin Synthesis and Signaling

Inhibition of COX-2 rapidly lowers the local concentration of inflammatory Prostaglandin E2 ( PGE2) within stressed tissues. This mechanism initiates a cascading effect that alters the physiological sensitization of peripheral pain receptors (nociceptors) and affects local vascular activity, contributing to modulation of fluid accumulation.

Mechanism of Sustained Local Engagement

The physiological duration of action is supported by the molecule's unique kinetics: it exhibits a slow dissociation rate from the COX-2 enzyme within inflamed tissues, even though its systemic presence may be brief. This sustained local engagement ensures continuous modulation of the target enzyme, allowing the effect on PGE2 activity to persist throughout the mechanistic interval.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Onsior (Robenacoxib) for Dogs

Onsior is administered either as an oral tablet or a subcutaneous (SC) injection. The labeled dosage is approximately 2 mg/kg body weight once daily for post-operative management, or 1 mg/kg for chronic osteoarthritis. Both the tablets and the injection may be used interchangeably, but the protocol is intended for only one dose per day, using the lowest effective dose for the shortest duration.


Administration Parameter Standard Parameters
Route of Administration Oral or Subcutaneous Injection.
Dosing Frequency Once daily (q24h).
Course Duration Limit For acute pain (e.g., post-operative), treatment typically does not exceed a maximum of 3 days.
Timing Relative to Food For oral use in osteoarthritis, administration occurs without food or at least 30 minutes before or after a meal. For post-operative oral use, it may be given with or without food.
Preparation Tablets are not scored and are not to be broken or divided. Dosage is achieved using whole tablet sizes.
Age and Weight For use in dogs at least 4 months of age and weighing at least 5.5 lbs (2.5 kg).

Procedural Rule: The initial dose for surgical procedures is administered approximately 30 to 45 minutes prior to surgery. The medication is not for concurrent administration with any other oral or injectable NSAID or corticosteroid.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Onsior for Dogs

The clinical evaluation of robenacoxib for dogs focuses on two primary areas: the management of acute discomfort immediately following surgery and the long-term management of chronic joint conditions. The official research evidence is drawn from controlled clinical field trials and supporting studies that helped regulators evaluate the clinical evidence.


Evidence for Use in Acute Post-operative Pain

Research examining robenacoxib was conducted through multiple randomized, blinded, placebo-controlled multicenter clinical field trials. These studies focused on dogs undergoing common procedures, which are conditions associated with acute or disruptive episodes of pain. The studies monitored several outcomes related to physical discomfort and function. Investigators and owners used validated pain scales to record patient-reported outcomes describing perceived discomfort and activity levels. Research noted patterns in measured pain scores and the frequency with which rescue pain medication was required between the groups evaluated. This research provides context regarding the short-term symptom patterns observed following surgical procedures.

It is important to note that follow-up durations were limited. The most critical data for regulatory approval focuses only on the first 3 consecutive days post-surgery. As a result, long-term effects are not fully established for continuous acute use beyond this specific short period, and results apply only to the populations studied in the trials.


Evidence for Chronic Osteoarthritis Management

For conditions characterized by fluctuating or episodic manifestations like osteoarthritis, research examined longer-term clinical field trials. These studies were applied in research contexts involving fluctuating or unstable symptoms where relief of discomfort and support for mobility were the central concerns. Studies monitored outcomes linked to inflammatory or irritative states, such as assessments of lameness and joint stiffness, over several weeks. Data show patterns related to measured changes in these symptomatic and functional measures in the observed populations. Evidence is limited regarding the long-term patterns for daily use extending beyond these observational periods.


Research Gaps and Areas of Uncertainty

Evidence regarding efficacy or safety beyond the maximum treatment duration of 3 days has not been fully established for acute use. Furthermore, subgroup findings are uncertain, as data for young, very old, or dogs with certain pre-existing conditions are not typically separated or detailed in the main regulatory summaries. Comparative evidence is lacking for certain clinical scenarios, and data are still emerging regarding patterns of outcomes in chronic care over many years.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Onsior for Dogs (FAQ)


Q: How quickly should I expect Onsior to start working after the first dose?

Official information indicates that the medicine is absorbed rapidly after a dog takes the tablet. Peak levels in the bloodstream are often reached within 30 minutes to one hour after administration without food. Research suggests a rapid onset of activity, which may be observed as early as 30 minutes.


Q: How long do the effects of one Onsior tablet usually last for a dog?

Onsior is designed for once-daily dosing, which indicates that a single dose is administered every 24 hours. The duration of the drug’s anti-inflammatory and pain-relieving effects is supported by its unique sustained engagement with the target enzyme at the site of inflammation.


Q: Is Onsior the same type of medicine as Rimadyl or Metacam?

Onsior belongs to the large pharmacological class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Its specific type is known as a selective Cyclooxygenase-2 (COX-2) inhibitor, which is a key characteristic of its function. Other common NSAIDs, such as those mentioned, may belong to different chemical or selectivity classes within the broader NSAID category.


Q: Can Onsior be given to dogs for long-term pain management?

For acute pain, such as following surgery, the regulatory documents specify that use should not exceed a maximum of three consecutive days. For chronic conditions like osteoarthritis, the use period is managed under veterinary direction. Safety data for continuous use extending beyond the original research periods is generally noted as being limited.


Q: What should I do if my dog vomits shortly after taking Onsior?

Regulatory documents indicate that if signs of drug intolerance are noted, such as vomiting, decreased appetite, or lethargy, it may be necessary to discontinue administration. Official information describes that in cases of overdose or severe reactions, the patient may receive supportive care, such as the administration of gastrointestinal protective agents.


Q: What is the maximum duration a dog is usually given Onsior for acute pain?

For controlling post-operative pain and inflammation associated with soft tissue surgery, the regulatory indication limits use to a maximum of three consecutive days. Safety for use extending beyond this specific period has not been demonstrated in the research reviewed for acute indications.


Q: Can Onsior be safely crushed or mixed with food?

The oral tablets are not scored and should not be broken or divided to split a dose. While the tablet may be given with or without food, especially for post-operative use, the entire, whole tablet must be used to achieve the prescribed dose.


Q: Is it okay to switch between different NSAIDs like Onsior and Meloxicam?

The concurrent use of Onsior with any other NSAID or corticosteroid is prohibited by official regulatory documents. When transitioning from one anti-inflammatory medicine to another, the label states that appropriate washout times must be considered.


Q: Can Onsior cause a change in a dog's appetite?

Yes, regulatory documents list decreased appetite, also known as anorexia or inappetence, as a common adverse reaction that has been reported. This is a common gastrointestinal change that has been observed.


Q: Is it safe to give Onsior with supplements like glucosamine or fish oil?

Official regulatory documents do not specifically list interactions with common supplements like glucosamine or fish oil. However, regulatory documents emphasize the importance of communicating all medicines, supplements, or herbal therapies a dog is receiving to the prescriber, as certain substances may require monitoring for potential interactions.


Q: What happens if a dog accidentally takes more Onsior than prescribed?

In cases of overdose or suspected drug intolerance, official regulatory information indicates that the patient may receive supportive care. This care may include fluid administration and the use of medicines intended to help protect the gastrointestinal tract.


Q: Does the manufacturer recommend any specific blood tests while a dog is on Onsior?

For dogs on long-term therapy, such as for osteoarthritis, regulatory documents contain information regarding the monitoring of liver enzymes. This monitoring is often done early in the treatment course and then regularly thereafter.


Q: Can Onsior cause behavioral changes in a dog?

The regulatory documents list behavioral changes as a potential adverse reaction. Owners are often advised to report any notable changes in disposition or activity level during the administration period.


Q: Is Onsior used for chronic pain other than arthritis?

The official indication (approved use) for chronic pain in dogs is specifically for the treatment of pain and inflammation associated with chronic osteoarthritis. Other potential uses for chronic pain are not formally indicated on the regulatory labels.


Q: How do scientists determine if a pain drug is effective in dogs?

The official research evidence is based on controlled clinical field trials, which are typically randomized, blinded, and placebo-controlled. These studies monitor outcomes related to the dog's physical discomfort and function, often using validated pain scales, and look at the frequency of rescue pain medication use.


Q: Is there a taste or flavor to the Onsior tablets that dogs prefer?

The oral tablets are described in regulatory documents as being flavored. This feature is included to help increase acceptance and ease administration for the dog. The specific nature of the flavor is generally not detailed in the official regulatory product information.


Q: Does Onsior have a different side effect profile compared to older NSAIDs?

Onsior is a highly selective COX-2 NSAID, which targets the enzyme responsible for inflammation while largely sparing those that protect the stomach. However, all drugs in the NSAID class are generally associated with potential risks to the gastrointestinal, renal (kidney), and hepatic (liver) systems. Sensitivity to adverse events can vary by patient.

Advertisements

How should Onsior for Dogs be stored and disposed of?

How to Store and Dispose of Onsior for Dogs?

The official storage and disposal requirements for Onsior (robenacoxib) are strictly defined by regulatory documents, varying based on the pharmaceutical form.

Official Storage Requirements

Dosage Form Mandatory Storage Condition In-Use Stability Constraint
Oral Tablets Store at controlled room temperature, not exceeding 25 C (77 F). Protect from moisture and light.
Injectable Solution Store in a refrigerator (2 C to 8 C) before opening. Use within 28 days after first opening the vial.

Child Safety and Disposal

It is officially mandated to keep both the tablets and the injectable solution out of the sight and reach of children and pets in a secure location. Unused or expired Onsior must not be disposed of via household waste or wastewater. The product and any waste materials must be discarded following local regulations established for medicinal products to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Onsior for Dogs found in:

A-Z Index: